Esketamine, marketed by Johnson & Johnson as Spravato, has evolved from a niche add-on therapy into a primary monotherapy for treatment-resistant depression (TRD), with sales reaching $1.7 billion in 2024. Recent data presented at Psych Congress Elevate suggests that long-term remission rates for the drug may be more durable than previously documented in clinical literature, potentially reshaping how clinicians approach patients who fail to respond to standard oral antidepressants.
How Does Esketamine Remission Compare to Traditional Antidepressants?
Standard oral antidepressants often see a sharp decline in efficacy after the first treatment failure. According to data from the National Institute of Mental Health’s STAR*D trial, remission rates for patients drop to approximately 14% to 15% by the time they reach their second medication.
In contrast, an analysis led by Rakesh Jain, MD, MPH, of the Texas Tech University School of Medicine, indicates that esketamine may offer a different trajectory. While the data remains descriptive—lacking formal meta-analysis or pooled effect estimates—the reported remission rates in long-term open-label studies reached 49.3% at one year and 78.2% at two-and-a-half years. These figures represent a stark contrast to the rapid drop-off observed in the STAR*D study, though experts note that these open-label figures only include patients who remained on the medication throughout the duration of the study.
Did you know?
The Montgomery-Åsberg Depression Rating Scale (MADRS) is the standard tool for measuring these outcomes. A score of 10 or below is the conventional threshold for clinical remission.
Why Do Clinical Opinions on Esketamine Vary?
The medical community remains divided on the clinical value of esketamine, largely due to differences in how various regulatory and guideline bodies interpret the evidence. The 2022 VA/DoD depression guidelines categorize the drug as a "weak for" recommendation, citing low-quality evidence and concerns regarding the feasibility of its required monitoring program.
Conversely, the head-to-head ESCAPE-TRD trial published in the New England Journal of Medicine showed that esketamine plus an SSRI or SNRI produced a 27.1% remission rate at eight weeks, compared to 17.6% for quetiapine extended-release. However, critics like Sanjay Mathew and Nicholas Murphy, writing in the American Journal of Psychiatry, argue that the narrow gap in depression scores—roughly 2.2 to 2.8 points on a 60-point scale—falls below the threshold for a "clinically meaningful difference."
What Are the Real-World Barriers to Prescription?
Physicians looking to prescribe Spravato must account for significant administrative and safety hurdles. The drug is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program.
According to the drug’s labeling, this program mandates:
- Administration in a certified healthcare setting.
- A mandatory two-hour monitoring period post-dose to observe for side effects like dissociation or respiratory depression.
- A strict prohibition against driving until the day following administration.
Dr. Jain suggests that these logistical requirements, combined with a natural inertia in psychiatric practice, contribute to the hesitation some clinicians feel when considering esketamine for patients who have not yet exhausted all other treatment options.
Pro Tip
When evaluating treatment options for TRD, clinicians are increasingly encouraged to look at both the short-term symptom reduction and the potential for long-term maintenance, rather than relying solely on initial response rates.
Frequently Asked Questions
Is esketamine approved to treat suicidal ideation?
The FDA has approved esketamine for the rapid reduction of depressive symptoms in patients with acute suicidal ideation, but the label specifies that it has not been proven to directly prevent suicide or reduce the frequency of suicidal thoughts.
What defines "treatment-resistant depression"?
Treatment-resistant depression is typically defined as failing to achieve an adequate response after two or more trials of standard oral antidepressants, according to research cited by Dr. Rakesh Jain.
How does the Spravato REMS program affect patient access?
The program requires patients to receive treatment in a certified facility and remain under medical observation for at least two hours, which can limit availability for patients in rural areas or those without reliable transportation.
Are you a healthcare provider or a patient navigating treatment-resistant depression? Share your experiences with new therapeutic modalities in the comments below, or subscribe to our newsletter for the latest updates on psychiatric clinical research.